[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"functional-bloating\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:functional-bloating":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100544505","visible-abdominal-distension-100544505",false,"NCT06369753","Visible Abdominal Distension","Tratamiento de la distensión Abdominal Funcional","Inclusion Criteria:\n\n* episodes of visible abdominal distension triggered by meal ingestion\n\nExclusion Criteria:\n\n* organic cause detected by clinical work-up\n* constipation\n* abdominal distension not confirmed by the 7-day clinical questionnaires in the pre- intervention evaluation",true,"ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background. Abdominal distention is produced by an abnormal somatic postural tone. The authors developed an original biofeedback technique. In a randomized, placebo-controlled trial the authors demonstrated the superiority of biofeedback over placebo for the treatment of abdominal distention. However, the technique is technically complex and unpractical.\n\nAim. To prove the efficacy of a noninstrumental biofeedback technique, transmitted by a standard training program, for the treatment of abdominal distension in different centers.\n\nSelection criteria. Episodes of visible abdominal distension. Intervention. Patients will be randomized into biofeedback and placebo groups. Three sessions of either biofeedback or placebo intervention will be performed during the first 3 weeks of the intervention period.\n\nBiofeedback: Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. In each center one operator will receive a standard training on how to deliver the noninstrumental biofeedback treatment. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.\n\nPlacebo: Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.",[28,29,30],"Irritable Bowel Syndrome","Dyspepsia","Functional Bloating","RECRUITING","2025-10-30",{"date":34,"type":35},"2025-10-31","ACTUAL",{"date":37,"type":35},"2025-07-30",{"date":39,"type":22},"2026-10",{"name":41,"class":42},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100532624","capsule-microbiota-sampling-in-ibsfunctional-gastrointestinal-disease-100532624","NCT06215222","Capsule Microbiota Sampling in IBS\u002FFunctional Gastrointestinal Disease","Inclusion Criteria:\n\n* Males or females 18 years of age or older and 70 years of age or younger at the time of the first Screening Visit.\n* American Society of Anesthesiologists (ASA) Physical Status Classification System 1 or 2 (1-A normal healthy patient or 2-A patient with mild systemic disease)\n* For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit. Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).\n* Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.\n* Positive for at least one clinical symptoms consistent with SIBO and or IBS and or a Rome Diagnosis of functional GI disorder (Rome IV criteria)\n\nExclusion Criteria:\n\n* History of any of the following:\n\n  * Prior gastric or esophageal surgery, including lap banding or bariatric surgery\n  * Bowel obstruction\n  * Gastric outlet obstruction\n  * Diverticulitis\n  * Inflammatory bowel disease\n  * Ileostomy or colostomy\n  * Gastric or esophageal cancer\n  * Achalasia\n  * Esophageal diverticulum\n* Active Dysphagia or Odynophagia\n* Active medication use for any gastrointestinal conditions\n* Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding\n* Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study","70 Years",{"count":52,"type":22},40,"OBSERVATIONAL","We will sample intestinal microbiota using a microbiome sampling capsule in Healthy, Irritable Bowel Syndrome (IBS), and Functional Gastrointestinal Disease.",[56,57,30,58],"IBS - Irritable Bowel Syndrome","Healthy","Functional Gastrointestinal Disorders",[60,61],"microbiome","Small intestine","2024-01-10",{"date":64,"type":35},"2024-01-22",{"date":66,"type":35},"2023-11-16",{"date":68,"type":22},"2026-12-01",{"name":70,"class":42},"Stanford University",1]